Skip to main content
ZoetisIn development

Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment

Source: Autobound Signal API · 77 signals tracked for Zoetis · updated

Get Zoetis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Zoetis this week? Use Autobound signals for zoetis.com.

What happened

Zoetis announced FDA approval for Convenia RTU for Dogs, with commercial availability expected in Q1 2027.

Source

Article excerpt

Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional PARSIPPANY, N.J.--(BUSINESS WIRE)-- $ZTS #animalhealth -- Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Convenia® RTU for Dogs (cefovecin injectable suspension) for the treatment of susceptible bacterial skin infections in dogs. For many families, administering oral antibiotics daily for one to two weeks can be difficult, especially when a dog resists medication or a household schedule makes routine timing hard to maintain. Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections in dogs and is administered by a veterinary health professional, supporting complete dose compliance. “Anyone who has tried to give a dog pills for a week or two knows how challenging it can be to stay on schedule. Convenia® (cefovecin sodium) has been a veterinarian-trusted treatment for susceptible bacterial skin infections for over a decade and has helped remove the burden of continued and accurate dosing that is typically required with oral antibiotics,” said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis. “With Convenia RTU for Dogs, we are building on the...

Keep reading with a free account

The rest of this article, and every signal for Zoetis, is in your free account.

Extracted from this sentence

Convenia RTU for Dogs is expected to be available to veterinarians in Q1 2027 as part of Zoetis’ expanding portfolio of products designed to broaden treatment options for all dogs, especially medium to large breeds.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
Convenia RTU for Dogs
Location
Parsippany, New Jersey, United States

The full record

From the Signal API record

Details

Ticker
NYSE:ZTS

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Oct 21, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Zoetis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Zoetis this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/8a21b40f-62ac-1041-c0cd-c3c3ef23c9a5 returns this record as JSON. POST /v1/companies/enrich returns every signal for zoetis.com.

{
  "signal_id": "8a21b40f-62ac-1041-c0cd-c3c3ef23c9a5",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-10-21T04:08:36+00:00",
  "company": {
    "name": "Zoetis",
    "domain": "zoetis.com"
  },
  "data": {
    "url": "https://www.biospace.com/press-releases/zoetis-receives-fda-approval-for-convenia-rtu-for-dogs-cefovecin-injectable-suspension-helping-more-medium-and-large-dogs-access-single-injection-treatment",
    "title": "Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment - BioSpace",
    "ticker": "NYSE:ZTS",
    "excerpt": "Convenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional PARSIPPANY, N.J.--(BUSINESS WIRE)-- $ZTS #animalhealth -- Zoetis Inc. (NYSE: ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Convenia® RTU for Dogs (cefovecin injectable suspension) for the treatment of susceptible bacterial skin infections in dogs. For many families, administering oral antibiotics daily for one to two weeks can be difficult, especially when a dog resists medication or a household schedule makes routine timing hard to maintain. Convenia RTU for Dogs provides up to 14 days of antibiotic treatment in a single dose for susceptible bacterial skin infections in dogs and is administered by a veterinary health professional, supporting complete dose compliance. “Anyone who has tried to give a dog pills for a week or two knows how challenging it can be to stay on schedule. Convenia® (cefovecin sodium) has been a veterinarian-trusted treatment for susceptible bacterial skin infections for over a decade and has helped remove the burden of continued and accurate dosing that is typically required with oral antibiotics,” said Abhay Nayak, Executive Vice President and President, U.S. Commercial Operations at Zoetis. “With Convenia RTU for Dogs, we are building on the...",
    "product": "Convenia RTU for Dogs",
    "summary": "Zoetis announced FDA approval for Convenia RTU for Dogs, with commercial availability expected in Q1 2027.",
    "location": "Parsippany, New Jersey, United States",
    "planning": true,
    "image_url": "https://static.biospace.com/dims4/default/d32393a/2147483647/strip/true/crop/1120x630+40+0/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Fcc%2F88%2Fa9fddaf440db946b77e1d45d2e26%2Fbiospace-5.png",
    "confidence": 0.95,
    "product_data": {
      "name": "Convenia RTU for Dogs",
      "full_text": "Convenia® RTU for Dogs (cefovecin injectable suspension)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-10-21T04:08:36Z",
    "location_data": [
      {
        "city": "Parsippany",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Convenia RTU for Dogs is expected to be available to veterinarians in Q1 2027 as part of Zoetis’ expanding portfolio of products designed to broaden treatment options for all dogs, especially medium to large breeds."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.